Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA

Executive Summary

FDA is reviewing Amphastar’s application for a new intranasal formulation at the same time it is reconsidering minimum pharmacokinetic standards for the opioid overdose reversal agent.

Advertisement

Related Content

Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
Unapproved Petitioner: Clinical-Stage Firm Wants FDA Scrutiny Of Naloxone Formulations
Drug Abuse And US Presidential Politics: Surprising Bipartisan Agreement
FDA’s Opioid Crisis Response: More Pressure For Treatment Drugs
Higher Naloxone Doses Narrowly Favored By FDA Panel
FDA’s Naloxone Product Approval Standards May See Changes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register